MA39342A1 - Anticorps il -21 - Google Patents

Anticorps il -21

Info

Publication number
MA39342A1
MA39342A1 MA39342A MA39342A MA39342A1 MA 39342 A1 MA39342 A1 MA 39342A1 MA 39342 A MA39342 A MA 39342A MA 39342 A MA39342 A MA 39342A MA 39342 A1 MA39342 A1 MA 39342A1
Authority
MA
Morocco
Prior art keywords
antibodies
methods
compositions
antagonism
neutralize
Prior art date
Application number
MA39342A
Other languages
English (en)
Other versions
MA39342B2 (fr
Inventor
Julian Davies
Fabio Magrini
Andrea Paula Martin
Neelufar Mozaffarian
Chetankumar Natvarlal Patel
Oliver Schroeder
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39342A1 publication Critical patent/MA39342A1/fr
Publication of MA39342B2 publication Critical patent/MA39342B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps humanisés construits qui ont une forte affinité de liaison pour il -21 humain et qui le neutralisent, des procédés d'utilisation desdits anticorps pour traiter des maladies dans lesquelles l'antagonisme ou la neutralisation des effets d'il -21 est garanti, telles que des maladies auto-immunes, des compositions et des procédés de production par recombinaison des anticorps, et des compositions pharmaceutiques comprenant lesdits anticorps.
MA39342A 2014-03-21 2015-03-13 Anticorps il -21 MA39342B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Publications (2)

Publication Number Publication Date
MA39342A1 true MA39342A1 (fr) 2018-03-30
MA39342B2 MA39342B2 (fr) 2020-03-31

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39342A MA39342B2 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Country Status (24)

Country Link
US (1) US9394362B2 (fr)
EP (1) EP3119806B1 (fr)
JP (2) JP6053989B2 (fr)
KR (1) KR101859857B1 (fr)
CN (1) CN106061999B (fr)
AP (1) AP2016009450A0 (fr)
AR (1) AR099625A1 (fr)
AU (1) AU2015231777B2 (fr)
BR (1) BR112016019176A2 (fr)
CA (1) CA2939543C (fr)
CL (1) CL2016002281A1 (fr)
EA (1) EA033335B1 (fr)
EC (1) ECSP16075416A (fr)
ES (1) ES2774422T3 (fr)
IL (1) IL246909A0 (fr)
MA (1) MA39342B2 (fr)
MX (1) MX2016012120A (fr)
MY (1) MY177915A (fr)
NZ (1) NZ722518A (fr)
PE (1) PE20161221A1 (fr)
PH (1) PH12016501820A1 (fr)
SG (1) SG11201606705QA (fr)
TW (1) TWI646105B (fr)
WO (1) WO2015142637A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
JP2018536650A (ja) * 2015-10-30 2018-12-13 ジェネンテック, インコーポレイテッド 抗d因子抗体変異体コンジュゲート及びその使用
CA3018792C (fr) 2016-03-31 2023-03-28 Eli Lilly And Company Anticorps contre il-21 et leurs utilisations
US11554131B2 (en) * 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
WO2020023702A1 (fr) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Nouveaux promédicaments d'il-21 et leurs procédés d'utilisation
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (fr) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
EP4017594A1 (fr) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Nouveaux promédicaments à base d'il-21 et leurs procédés d'utilisation
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024525613A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
US20240318176A1 (en) * 2021-07-09 2024-09-26 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (fr) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Complexes ciblant le muscle et formulations de traitement de dystrophinopathies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
EP1960433A2 (fr) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Antagonistes du recepteur de il-21
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
EP2217268B1 (fr) * 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anticorps monoclonaux anti-il-21 humain
SI2796466T1 (en) * 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
WO2012164021A1 (fr) * 2011-05-31 2012-12-06 Novo Nordisk A/S Epitopes de il-21 et ligands de il-21

Also Published As

Publication number Publication date
JP2017093435A (ja) 2017-06-01
JP2016520088A (ja) 2016-07-11
MX2016012120A (es) 2016-12-09
PH12016501820A1 (en) 2016-11-07
TW201623330A (zh) 2016-07-01
KR101859857B1 (ko) 2018-05-18
NZ722518A (en) 2017-12-22
IL246909A0 (en) 2016-09-29
ECSP16075416A (es) 2018-05-31
EP3119806A4 (fr) 2017-11-01
AU2015231777A1 (en) 2016-08-18
PE20161221A1 (es) 2016-11-12
TWI646105B (zh) 2019-01-01
JP6053989B2 (ja) 2017-01-11
BR112016019176A2 (pt) 2017-10-10
EA201691521A1 (ru) 2017-02-28
SG11201606705QA (en) 2016-09-29
JP6373944B2 (ja) 2018-08-15
AR099625A1 (es) 2016-08-03
EP3119806A1 (fr) 2017-01-25
WO2015142637A1 (fr) 2015-09-24
CL2016002281A1 (es) 2017-06-23
MA39342B2 (fr) 2020-03-31
US20150266954A1 (en) 2015-09-24
EP3119806B1 (fr) 2020-01-01
CA2939543A1 (fr) 2015-09-24
EA033335B1 (ru) 2019-09-30
MY177915A (en) 2020-09-25
AP2016009450A0 (en) 2016-09-30
CN106061999A (zh) 2016-10-26
US9394362B2 (en) 2016-07-19
CN106061999B (zh) 2020-07-31
KR20160124166A (ko) 2016-10-26
ES2774422T3 (es) 2020-07-21
CA2939543C (fr) 2018-01-16
AU2015231777B2 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
MA39342B2 (fr) Anticorps il -21
MX2025009223A (es) Agentes de union a clec9a y su uso
WO2018069500A3 (fr) Anticorps anti-lag-3 et compositions
EP4406554A3 (fr) Formulations d'anticorps anti-cd3
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
EP4413985A3 (fr) Composés pharmaceutiques
EP4628094A3 (fr) Anticorps baff-r et utilisations de ceux-ci
WO2017106346A3 (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
WO2017049038A3 (fr) Anticorps anti-cd115
EP4636085A3 (fr) Compositions pour moduler l'expression de mecp2
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2021005085A (es) Formulacion de anticuerpo.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
WO2018129451A3 (fr) Anticorps anti-fgfr et procédés d'utilisation
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул